AU2008293845B2 - Compounds for the treatment of hepatitis C - Google Patents

Compounds for the treatment of hepatitis C Download PDF

Info

Publication number
AU2008293845B2
AU2008293845B2 AU2008293845A AU2008293845A AU2008293845B2 AU 2008293845 B2 AU2008293845 B2 AU 2008293845B2 AU 2008293845 A AU2008293845 A AU 2008293845A AU 2008293845 A AU2008293845 A AU 2008293845A AU 2008293845 B2 AU2008293845 B2 AU 2008293845B2
Authority
AU
Australia
Prior art keywords
cyclohexyl
methoxy
indolo
benzazepine
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008293845A
Other languages
English (en)
Other versions
AU2008293845A1 (en
Inventor
Carl P. Bergstrom
Robert G. Gentles
Scott W. Martin
Kap-Sun Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2008293845A1 publication Critical patent/AU2008293845A1/en
Application granted granted Critical
Publication of AU2008293845B2 publication Critical patent/AU2008293845B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008293845A 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis C Ceased AU2008293845B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US60/954,814 2007-08-09
US4994408P 2008-05-02 2008-05-02
US61/049,944 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
US12/180,994 2008-07-28
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (2)

Publication Number Publication Date
AU2008293845A1 AU2008293845A1 (en) 2009-03-05
AU2008293845B2 true AU2008293845B2 (en) 2013-02-14

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008293845A Ceased AU2008293845B2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis C

Country Status (18)

Country Link
US (1) US7652004B2 (cg-RX-API-DMAC7.html)
EP (1) EP2183252B1 (cg-RX-API-DMAC7.html)
JP (1) JP5465670B2 (cg-RX-API-DMAC7.html)
KR (1) KR20100066492A (cg-RX-API-DMAC7.html)
CN (1) CN101821267B (cg-RX-API-DMAC7.html)
AR (1) AR067897A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008293845B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0814931A2 (cg-RX-API-DMAC7.html)
CA (1) CA2695781A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008002353A1 (cg-RX-API-DMAC7.html)
CO (1) CO6251359A2 (cg-RX-API-DMAC7.html)
EA (1) EA015978B1 (cg-RX-API-DMAC7.html)
MX (1) MX2010001416A (cg-RX-API-DMAC7.html)
NZ (1) NZ583149A (cg-RX-API-DMAC7.html)
PE (1) PE20090618A1 (cg-RX-API-DMAC7.html)
TW (1) TW200906418A (cg-RX-API-DMAC7.html)
WO (1) WO2009029384A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201000923B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049622A1 (ja) * 2003-11-19 2005-06-02 Japan Tobacco Inc. 5-5員縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2209789B1 (en) * 2007-11-20 2011-11-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2012176717A1 (ja) * 2011-06-22 2012-12-27 セントラル硝子株式会社 ピラゾール化合物の製造方法
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033032A1 (en) * 2005-09-12 2007-03-22 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A2 (en) * 2006-02-08 2007-08-16 Bristol-Myers Squibb Company Hcv ns5b inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007033032A1 (en) * 2005-09-12 2007-03-22 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
WO2007092888A2 (en) * 2006-02-08 2007-08-16 Bristol-Myers Squibb Company Hcv ns5b inhibitors

Also Published As

Publication number Publication date
US7652004B2 (en) 2010-01-26
EA015978B1 (ru) 2012-01-30
PE20090618A1 (es) 2009-05-16
CO6251359A2 (es) 2011-02-21
TW200906418A (en) 2009-02-16
CN101821267B (zh) 2013-07-10
MX2010001416A (es) 2010-03-01
EA201000277A1 (ru) 2010-06-30
EP2183252B1 (en) 2015-01-14
KR20100066492A (ko) 2010-06-17
WO2009029384A2 (en) 2009-03-05
WO2009029384A3 (en) 2009-05-28
NZ583149A (en) 2011-07-29
CL2008002353A1 (es) 2008-10-24
AR067897A1 (es) 2009-10-28
JP5465670B2 (ja) 2014-04-09
EP2183252A2 (en) 2010-05-12
CN101821267A (zh) 2010-09-01
CA2695781A1 (en) 2009-03-05
AU2008293845A1 (en) 2009-03-05
US20090074715A1 (en) 2009-03-19
BRPI0814931A2 (pt) 2015-02-03
JP2010535787A (ja) 2010-11-25
ZA201000923B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
EP2183252B1 (en) Compounds for the treatment of hepatitis c
AU2007211988B2 (en) HCV NS5B inhibitors
US7348425B2 (en) Inhibitors of HCV replication
EP2024375B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
EP2178878B1 (en) Tetracyclic compounds for the treatment of hepatitis c
US20080227769A1 (en) Compounds for the Treatment of Hepatitis C
EP2280975B1 (en) 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c
AU2009228337A1 (en) Compounds for the treatment of hepatitis C
US8143243B2 (en) Compounds for the treatment of hepatitis C
EP2396329B1 (en) Compounds for the treatment of hepatitis c
HK1122814B (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired